Clinical Study of Hypofractionated Radiotherapy Combined with Temozolomide and Bevacizumab in the Treatment of Newly Diagnosed Postoperative Glioblastoma
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · e113
DOI: 10.1016/j.ijrobp.2026.06.899 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von C. Wang und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, C., Tu, H., Fan, C., Tang, Z., Luo, Q., & Luo, Y. (2026). Clinical Study of Hypofractionated Radiotherapy Combined with Temozolomide and Bevacizumab in the Treatment of Newly Diagnosed Postoperative Glioblastoma. International Journal of Radiation Oncology*Biology*Physics, 126(1), e113. https://doi.org/10.1016/j.ijrobp.2026.06.899
Vancouver
Wang C, Tu H, Fan C, Tang Z, Luo Q, Luo Y. Clinical Study of Hypofractionated Radiotherapy Combined with Temozolomide and Bevacizumab in the Treatment of Newly Diagnosed Postoperative Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):e113. doi:10.1016/j.ijrobp.2026.06.899
BibTeX
@article{Wang2026,
author = {Wang, C. and Tu, H. and Fan, C.B. and Tang, Z. and Luo, Q. and Luo, Y.},
title = {Clinical Study of Hypofractionated Radiotherapy Combined with Temozolomide and Bevacizumab in the Treatment of Newly Diagnosed Postoperative Glioblastoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {e113},
doi = {10.1016/j.ijrobp.2026.06.899}
}
EUVIMED